UNITED STATES DISTRICT COURT EASTERN DISTRICT OF LOUISIANA

In Re: TAXOTERE (DOCETAXEL)
PRODUCTS LIABILITY LITIGATION

MDL NO. 2740

SECTION "H" (5)

THIS DOCUMENT RELATES TO ALL CASES

JOINT REPORT NO. 16 OF LIAISON COUNSEL (Status Conference, April 4, 2019)

NOW INTO COURT come Plaintiffs' Co-Liaison Counsel ("PLC") and Defendants' Liaison Counsel ("DLC"), who respectfully submit this Joint Report No. 16 of Liaison Counsel.

1. REPORT OF CLAIMS AND CASE INVENTORY

On October 4, 2016, the Judicial Panel on Multidistrict Litigation ("JPML") transferred 28 civil action(s) to the United States District Court for the Eastern District of Louisiana for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See In re Taxotere* (*Docetaxel*) *Prod. Liab. Litig.*, MDL 2740, 2016 WL 5845996 (U.S. Jud. Pan. Mult. Lit. Oct. 4, 2016). Since that time, additional actions have been transferred to the Eastern District of Louisiana pursuant to Conditional Transfer Orders of the Judicial Panel on Multidistrict Litigation ("JPML"). On May 16, 2018, the JPML reassigned MDL. No. 2740 to the Honorable Judge Jane Triche Milazzo. (Doc. 2599). As of April 1, 2019, there are approximately 11,506 cases pending in the MDL before the Honorable Jane Triche Milazzo, with approximately 1,509 cases that have been closed, dismissed, or remanded since inception of the MDL.

2. FEDERAL/STATE COORDINATION

Related state court proceedings are pending in California, New Jersey, Delaware, and Mississippi. Some state court cases were removed to federal court. This Court ruled on remand

1

motions on August 30, 2017, May 15, 2018, and October 3, 2018. (Rec. Docs. 781, 2597, 4517).

On February 7, 2018, the Court entered Pretrial Order No. 77 (Rec. Doc. 1633) to streamline the briefing of future motions to remand by California Plaintiffs who name McKesson as a non-diverse defendant. Pretrial Order No. 77 has since been superseded by Pretrial Order No. 77A (Rec. Doc. 2202), in order to clarify the date on which a case is "docketed" in the MDL.

On March 29, 2019, Plaintiffs in *Jones et al. v. Sanofi U.S. Services Inc., et al*, No. 2:19-cv-01164, filed a Motion to Remand the case. (Rec. Doc. 6597). The parties have notified Plaintiff's counsel of the provisions of PTO No. 65 (Procedure for Severance of Multi-Plaintiff Cases) (Rec. Doc. 959) and PTO No. 77A, (California Plaintiffs' Motion to Remand) requiring "Plaintiffs who file cases in California Superior Courts naming McKesson as a Defendant . . . [to] meet and confer in an attempt to resolve the remand issue prior to submission of any briefing. . . . "including by the plaintiff". . . provid[ing] any information possessed concerning McKesson's alleged connection to the Plaintiff's use of Taxotere/docetaxel (including the Plaintiff's treatment time period, and the facility where Taxotere/docetaxel was administered to the Plaintiff) within seven (7) days of the case being docketed in this MDL." (Rec. Doc. 2202).

The Attorney General for the State of Mississippi filed *Jim Hood*, *Attorney General of the State of Mississippi*, *ex rel*. *The State of Mississippi* v. *Sanofi S.A.*, *et al.* in the Chancery Court of Hinds County, Mississippi. Sanofi removed the case to the Southern District of Mississippi and tagged the case for transfer to the MDL with the JPML. The Attorney General filed a Motion to Remand and opposed MDL transfer which the JPML granted. The case was remanded to the Chancery Court of Hinds County, Mississippi.

Pursuant to PTO No. 8 (Rec. Doc. 156), counsel for each Defendant shall provide to Plaintiffs' Federal-State Liaison Counsel all relevant information on the cases pending in state

court, the contact information for each state court Judge; as well as provide copies of all state court complaints. The parties continue to coordinate and communicate with all counsel and advise them of the status conference call-in number (listen only). The parties also continue to make efforts to identify the relevant state court judge(s) and provide their information to the Court. The parties understand the Court has made or will make contact with these judges to apprise them of the MDL and the Court's willingness to coordinate discovery and other pretrial proceedings. The Court has been in communication with the Honorable Judge Vivian Medinilla of Delaware as Judge Medinilla has many cases in her court that were remanded from this Court. The New Jersey Supreme Court ordered centralized case management of Taxotere cases filed in New Jersey on July 17, 2018, and designated the Honorable James F. Hyland of Middlesex County to preside over that litigation. At the time of the February 21, 2019 status conference there were 184 cases pending in New Jersey before Judge Hyland. Judge Hyland's next status conference is April 18, 2019. Judge Hyland has joined Status Conferences before this Court by phone.

Federal-state Liaison Counsel provided the Court with the names and contact information for the state court judges, as well as a chart of state court case information.

3. PRETRIAL ORDERS

A listing of all Pretrial Orders is attached to this Joint Report as Appendix A.16.

The Court has issued the following Pretrial Order (sometimes "PTOs") since the February 21, 2019 Status Conference:

A. PTO 94 (Rec. Doc. 6516) entered March 12, 2019, setting a status conference for April 4, 2019 and providing the call-in number for counsel to listen, which is (800) 260-0712, and with access code 465448.

4. CASE MANAGEMENT ORDERS

A listing of all Case Management Orders is attached to this Joint Report as Appendix B.16. The Court issued the following Case Management Orders (sometimes "CMOs") since the February 21, 2019 Status Conference:

- A. CMO 17 (Rec. Doc. 6550) entered on March 22, 2019, ordering that for any filing exceeding 50 pages in length, counsel is required to deliver a hard copy of the filing and all exhibits to the Court; and
- B. CMO 18 (Rec. Doc. 6551) entered on March 22, 2019, ordering that the first bellwether trial previously set for May 13-24, 2019, is continued to September 16-27, 2019.

5. COUNSEL CONTACT INFORMATION FORM

All counsel in the MDL are required to complete the Counsel Contact Information Form (available as a fillable PDF on the Court's MDL 2740 website) attached to PTO No. 7 (Rec. Doc. 155), and forward it to Plaintiffs' Liaison Counsel ("PLC") at taxotere@bkc-law.com. This information must be provided by Plaintiffs' counsel when counsel files the first MDL case and be kept current by each counsel as it will be relied upon throughout the litigation for updated information to Plaintiffs' counsel. The PLC provides a copy of all Counsel Contact Forms to Jacob Woody at BrownGreer. BrownGreer will rely on the information included in the Counsel Contact Form to serve all pleadings.

6. MASTER COMPLAINT AND SHORT FORM COMPLAINT

The Second Amended Master Long Form Complaint attached to Pretrial Order No. 82 (Rec. Doc. 4230) and the exemplar Short Form Complaint (Rec. Doc. 1463-1), are the effective and operative complaints for Plaintiffs. The exemplar Short Form Complaint, as amended on January 4, 2019, is available on the Court's MDL 2740 website under the tab "Forms" or on MDL

Centrality. All Defendants have filed Master Answers (Rec. Docs. 955, 956, 957, 958, 960, 961, 963, 969, 4704, and 4705).

Should a Plaintiff wish to file an Amended Complaint, the Court's Local Rule 7.6¹ requires that before filing any motion for leave to amend pleadings, Plaintiff must attempt to obtain the consent for the filing and granting of the motion from all parties having an interest to oppose. Pretrial Order No. 37A (Rec. Doc. 1682) sets forth the procedure that must be followed before filing a motion to amend a prior complaint, including amending a Short Form Complaint. Counsel for Plaintiff must contact in writing Defendant Liaison Counsel ("DLC") (John Olinde, olinde@chaffe.com, and Douglas Moore, dmoore@irwinllc.com) and the Contact Person listed on Exhibit B to Pretrial Order No. 37A (Rec. Doc. 1682) for each Defendant(s) presently named and for any Defendant sought to be added to the lawsuit, for consent or opposition to the proposed motion, at least fourteen (14) days in advance of filing the motion.² If no notice of any opposition is received by Plaintiff's counsel from any Defendant within the fourteen (14) day period, Plaintiff may file the motion for leave to amend as unopposed. If any opposition is received by Plaintiff's counsel from any Defendant within the fourteen (14) day period, a motion for leave to amend the pleadings must be filed as an opposed motion. If consent is obtained or no opposition is received in the fourteen (14) day period, the motion need not be assigned a submission date, but must be accompanied by a proposed order and include a certification by counsel for Plaintiff of the consent of opposing counsel or that no opposition was received from opposing counsel in the fourteen (14) day period.

Additionally, should any Plaintiff's counsel use the Short Form Complaint as an amending

¹ http://www.laed.uscourts.gov/sites/default/files/local rules/LAEDLocalCivilRules 4.pdf

² The request should include the proposed motion, order and amending pleading, as well as documentation supporting product identification (if available).

complaint, and not include all Defendants named in any earlier complaint, the Clerk's office will close that Plaintiff's claims against the Defendant(s) who is (are) not named in the amended complaint.

Moreover, attention must be paid to amendments entailing voluntary dismissal of the entire case. Under paragraph "J" of PTO 15 (Rec. Doc. 230), Plaintiffs cannot "notice" a voluntary dismissal of all Defendants without prejudice. They must either file a stipulation to dismiss or move to dismiss with prejudice. Dismissals with prejudice of those defendants whose product was not used, but not a dismissal of an entire action, must follow the form approved by the Court as Exhibit C to Case Management Order No. 12A: Product Identification Order (Rec. Doc. 3492).

On November 27, 2018, the Court entered PTO 87 which ordered procedures for the dismissal with prejudice by any non-Trial Pool Plaintiff as to the entire action against all defendants in the MDL. (Rec. Doc. 5363). The Form Dismissal to be used by Plaintiffs is attached as Exhibit A to PTO 87. (Rec. Doc. 5363-1).

7. PLAINTIFF AND DEFENDANT FACT SHEETS

Counsel should note the rules of the PFS in several Pretrial Orders:

- A. PTO 18 (Rec. Doc. 236) provides the form of the (prior) PFS and current Defendant Fact Sheet ('DFS");
- B. Amended PTO 22 (Rec. Doc. 325) sets forth the process for service of PFS and DFS, and the deadlines for service and deficiencies related to PFS and DFS;
- C. PTO 23 (Rec. Doc. 280) provides the form of authorizations attached to the PFS (Rec. Doc. 236-1);
- D. PTO 24 (Rec. Doc. 279) provides additional details on the service of fact sheets and authorizations through MDL Centrality and the PLC Distribution of Orders and Notices

per PTO 1;

- E. PTO 55 (Rec. Doc. 688) updated the form of the PFS.³ See Exhibit A to PTO 18 (Rec. Doc. 236-1); and
- F. PTO 22A (Rec. Doc. 3493) provides the show cause process for PFS deficiencies and for alleged failures to comply with CMO 12A and PTO 71A.

As of April 1, 2019, Plaintiffs have served 10,044 PFSs, and 1,256 are in progress. Based on the PFSs received as of April 1, 2019, they divide among Defendants as follows: 5,313 sanofi, 1,092 Hospira, 411 Sandoz, 298 Accord, 4 Sun, 1,482 Unknown, 329 Blank, and 1,115 Other/Miscellaneous. The PLC has advised all Plaintiffs' counsel of the Court's statements on the issue of photographs, and enclosed copies of the transcript where the Court expressed its expectation. Counsel should also familiarize themselves with PTO No. 68 (Rec. Doc. 1085) with regard to the requirements of representative, dated photographs taken closest in time to starting treatment and in no event earlier than five (5) years before then. The parties strive to work together and meet and confer on all alleged deficiencies in the Fact Sheets with the goal of narrowing the number of cases in dispute.

Consistent with Pretrial Order No. 22A, the Defendants submitted to Plaintiffs' Liaison Counsel Notices of Non-Compliance on February 1, 2019, and submitted their 14-Day Notice of Non-Compliance Cases Subject to the April 4, 2019 Dismissal Call Docket on March 20, 2019 (Rec. Doc. 6547). Attached to the 14-Day Notice is the list of cases they allege remain subject to dismissal. The list identifies 1440 plaintiffs. At the conclusion of the General Status Conference and oral argument on certain dispositive motions, the Court will recess for a short period of time

³ A fillable form of the PFS can be found on the "Forms" tab of the Court's MDL 2740 website and on Brown Greer's MDL Centrality website.

and will then begin the April Call Docket proceeding. Counsel with cases on the Notice of Non-Compliance Cases Subject to the April 4, 2019 Dismissal Call Docket can appear in person or via telephone. (Rec. Doc. 6516). The call-in number is 800-260-0712 and the access code is 465448.

In addition, on February 13, 2019, the Court conferred with the parties' designated counsel concerning the Show Cause process. The Court directed liaison counsel to remind all parties and individual counsel in the MDL that statements asserting the lack of photographs should be submitted only in response to the Court's order at a show cause hearing (and should not be submitted preemptively), must be signed under penalty of perjury, should identify the specific reason why responsive photographs do not exist, and must include an acknowledgement that plaintiff may be subject to sanctions for misrepresentations related to the existence of photographs or lack thereof.

8. SERVICE ON DEFENDANTS

Counsel for the Defendants and the Plaintiffs' Steering Committee ("PSC") have agreed to streamlined service procedures for each Defendant. The relevant Orders are:

- PTO 9 (Rec. Doc. 160) for service of complaints on the domestic sanofi entity⁴;
- PTO 29 (Rec. Doc. 303) for Accord Healthcare, Inc.;
- PTO 30 (Rec. Doc. 304) for Sandoz Inc.;
- PTO 32A (Rec. Doc. 710) for Actavis Pharma, Inc.:
- PTO 33 (Rec. Doc. 308) for McKesson Corporation;
- PTO 39A (Rec. Doc. 711) for Sun Pharmaceutical Industries, Inc. f/k/a Caraco
 Pharmaceutical Laboratories, LTD.;
- PTO 40A (Rec. Doc. 509) for Hospira Worldwide, LLC.; and,

⁴ Sanofi acknowledges that service of a complaint naming Winthrop US may be made on sanofi-aventis US LLC.

• PTO 83 (Rec. Doc. 4263) for Sagent Pharmaceuticals, Inc.

9. PRODUCT IDENTIFICATION ORDER

On July 18, 2018, the Court entered Case Management Order No. 12A: Product Identification Order (Rec. Doc. 3492) that sets forth the obligations and procedures governing discovery of Product ID Information and subsequent dismissal of defendants whose product was not used. Exhibit A to CMO 12A lists the email address of all defense counsel who should be notified pursuant to CMO 12A. Exhibit B is a new Statement Regarding Chemotherapy Administered, which includes new/updated NDC numbers. Counsel are reminded to use this new Exhibit B Statement when sending requests to infusion facilities. Exhibit C to CMO 12A provides the form for noticing voluntary dismissal with prejudice of the defendants not identified by Product ID Information. The PSC has been advised by certain counsel in the MDL that there are compliance issues with regard to subpoenas issued in connection with CMO 12A. The parties are meeting and discussing this issue.

10. PRESERVATION ORDER

Counsel are reminded to familiarize themselves with the terms of PTO 1 (Rec. Doc. 4, ¶12) regarding preservation of evidence. In addition, counsel are reminded of the preservation requirement in CMO 15 (Rec. Doc. 5008, ¶3) related to biopsies performed on plaintiffs for evaluation of hair loss.

11. PROTECTIVE ORDER

Magistrate Judge North entered the Protective Order on July 5, 2017, as PTO 50 (Rec. Docs. 612-1, 613).

12. ELECTRONICALLY STORED INFORMATION (ESI) DISCOVERY

Magistrate Judge North entered the Electronically Stored Information Protocol on July 5, 2017 as PTO 49 (Rec. Docs. 611-1, 613).

On January 26, 2018, the Court entered Pretrial Order No. 71A (Rec. Doc. 1531), which amends and supersedes Pretrial Order No. 71. Pretrial Order No. 71A sets forth Plaintiffs' Responsibilities Relevant to ESI and requires specific searches and a certification of compliance by both Plaintiff and Plaintiff's Counsel.

On November 13, 2018, the Court entered Pretrial Order No. 85 (Rec. Doc. 5257) which is the protocol for Defendants to raise PTO 71A and privilege log deficiencies of Non-Bellwether Plaintiffs before Magistrate Judge North. Counsel are reminded to review the procedures for deficiencies raised by the Defendants regarding ESI and privilege logs in PTO 85 as the procedure for the Show Cause Order Process before Magistrate Judge North is slightly different from the Show Cause Order Process before Judge Milazzo. On February 15, 2019, the Defendants submitted a PTO 85 Notice of Deficiency Determination spreadsheet, identifying certain ESI deficiencies. On February 19, 2019 the Defendants submitted their final Notice of Deficiency Determination, which included 32 Plaintiffs with outstanding ESI deficiencies. The first PTO 85 call docket was held on March 17, 2019, at which time the Court issued rulings applicable to all MDL Plaintiffs. A Minute Entry on the rulings followed on April 1, 2019. (Rec. Doc. 6614). The next PTO 85 call docket will take place on May 28, 2019. *Id.*

13. <u>DISCOVERY OF DEFENDANTS AND TRIAL CASE DISCOVERY</u>

Plaintiffs have served merits discovery on Sanofi, and the Sanofi Defendants have begun the process of producing responsive documents. Plaintiffs have also served merits discovery on Accord Healthcare, Inc., the Hospira/Pfizer Defendants, and Sandoz Inc. and have begun to receive

productions. The parties meet and confer about discovery and bring any unresolved issue to Magistrate Judge North. The next in-person status conference has been scheduled for April 23, 2019, at 10:00 a.m. (Rec. Doc. 6614).

Trial case discovery for *Francis* (primary plaintiff for the first trial)⁵, and *Earnest* (alternate plaintiff for the first trial) concluded on November 7, 2018, with plaintiffs issuing their expert reports on November 9, 2018. Sanofi Defendants issued expert reports on December 10, 2018, December 14, 2018, December 31, 2018, January 11, 2019, and January 31, 2019, in accordance with the Court's November 7, 2018 Order. (Rec. Doc. 5009). Sanofi's general liability discovery closed on December 15, 2018, pursuant to CMO No. 5. (Rec. Doc. 762); however, the parties are in the process of completing remaining depositions. The parties filed initial dispositive and expert motion practice on February 8, 2019. Subsequently, following the untimely production of certain additional histological slides by Plaintiffs' expert, Curtis Thompson, the deadlines for opposing some of these Motions were continued. The status of these Motions and Oppositions are discussed in further detail in the "Motion Practice" section, *infra*.

Discovery is ongoing in the trial pool cases available for subsequent trials as set forth in CMO 14A. On January 29, 2019, in CMO 16, the Court selected the following Trial Plaintiffs for the second bellwether trial: Cynthia Thibodeaux (primary Plaintiff) and Sheila Crayton (alternate Plaintiff). (Rec. Doc. 6017). Plaintiffs filed a Motion to remove Sheila Crayton from the trial pool on March 22, 2019. (Rec. Doc. 6559). This Motion is also discussed in further detail in the "Motion Practice" section, *infra*.

⁵ On February 7, 2019, the Court ruled that the original primary plaintiff for the first trial, Antoinette Durden, should not proceed as a bellwether case. (Rec Doc. 6120).

14. MOTION PRACTICE

On January 7, 2019, the Sanofi Defendants filed Motions for Summary Judgment with regard to three Plaintiffs' cases: Kelly Gahan (Rec. Doc. 5730); Jacqueline Mills (Rec. Doc. 5732); and Deborah Johnson (Rec. Doc. 5734). On February 27, 2019, Plaintiff Kelly Gahan filed a Consent Motion to Continue the Submission Date by agreement of all parties. (Rec. Doc. 6353). The Court has ordered that the parties file a Joint Notice of Submission Date no later than June 15, 2019. (Rec. Doc. 6484).

On February 26, 2019, Plaintiff Jacqueline Mills filed her Opposition to Defendants' Motion for Summary Judgment. (Rec. Doc. 6347). On March 1, 2019, Defendants filed their Motion for Leave to File Reply Memorandum regarding the *Mills* Motion for Summary Judgment. (Rec. Doc. 6373). On March 19, 2019, Plaintiff Deborah Johnson filed her Opposition to Defendants' Motion for Summary Judgment. (Rec. Doc. 6536). On March 26, 2019, Defendants filed their Motion for Leave to File Reply Memorandum regarding the *Mills* Motion for Summary Judgment. (Rec. Doc. 6576).

On March 22, 2019, the Court entered an Order setting Oral Argument on the *Mills* and *Johnson* Motions for Summary Judgment for April 4, 2019. (Rec. Doc. 6552).

On February 5, 2019, sanofi filed the following motions:

Motion for Summary Judgment on Causation-Learned Intermediary and Statute of Limitations with regard to three Plaintiffs' cases: Antoinette Durden (Rec. Doc. 6076 and 6077); Barbara Earnest (Rec. Doc. 6078 and 6079); and Tanya Francis (Rec. Doc. 6080 and 6081).

On February 8, 2019, sanofi filed the following motions:

- Motion to Exclude Linda Bosserman (Rec. Doc. 6130);
- Motion to Exclude Javid Moslehi (Rec. Doc. 6138);

- Motion to Exclude John Thompson (Rec. Doc. 6141);
- Motion to Exclude David Madigan (Rec. Doc. 6144);
- Motion to Exclude David Kessler (Rec. Doc. 6146);
- Motion to Exclude Ellen Feigal (Rec. Doc. 6149);
- Motion to Exclude Kevin Bianchini (Rec. Doc. 6151);
- Motion to Exclude Alan Bauman (Rec. Doc. 6153);
- Motion to Exclude Laura Plunkett (Rec. Doc. 6155);
- Omnibus Motion to Preclude Improper Expert Testimony (Rec. Doc. 6158);
- Motion to Exclude Expert Testimony of Specific Causation (Rec. Doc. 6162);
- Motion to Exclude Expert Testimony of General Causation (Rec. Doc. 6162); and
- Motion for Summary Judgment based on Preemption (Rec. Doc. 6186).

On the same date, Plaintiffs filed the following motions:

- Motion to Exclude David Spiegel (Rec. Doc. 6140);
- Motion to Exclude Vivian Fonseca (Rec. Doc. 6147); and
- Motion to Exclude Testimony that relies on Dr. Michael Kopreski (Rec. Doc. 6160).

Subsequently, following the untimely production of certain additional histological slides by Plaintiffs' expert, Curtis Thompson, the deadlines for opposing some of these Motions were continued. The Oppositions to certain Motions *not impacted* by the production of the additional slides were due on March 29, 2019. The parties have proposed that the Court's hearing on these "non-impacted Motions" take place on the week of May 6, 2019. These Motions include:

Defendants' Motion for Summary Judgment on Causation (Learned Intermediary)
 in Barbara Earnest (Rec. Doc. 6078);

- Defendants' Motion for Summary Judgment on Statute of Limitations in Barbara
 Earnest (Rec. Doc. 6079);
- Defendants' Motion for Summary Judgment on Causation (Learned Intermediary)
 in Tanya Francis (Rec. Doc. 6080);
- Defendants' Motion for Summary Judgment on Statute of Limitations in Tanya
 Francis (Rec. Doc. 6081);
- Defendants' Motion to Exclude Alan Bauman (Rec. Doc. 6153);
- Defendants' Motion to Exclude Linda Bosserman (Rec. Doc. 6130);
- Plaintiffs' Motion to Exclude Vivian Fonseca, M.D. (Rec. Doc. 6147); and
- Plaintiffs' Motion to Exclude David Spiegel, M.D. (Rec. Doc. 6594).

Plaintiff filed Oppositions to the following Motions on March 29, 2019:

- Opposition to Defendants' Motion for Summary Judgment on Causation (Learned Intermediary) in Barbara Earnest (Rec. Doc. 6604);
- Opposition to Defendants' Motion for Summary Judgment on Statute of Limitations in Barbara Earnest (Rec. Doc. 6611);
- Opposition to Defendants' Motion for Summary Judgment on Causation (Learned Intermediary) in Tanya Francis (Rec. Doc. 6606);
- Opposition to Defendants' Motion for Summary Judgment on Statute of Limitations in Tanya Francis (Rec. Doc. 6610);
- Opposition to Defendants' Motion to Exclude Alan Bauman (Rec. Doc. 6599); and
- Opposition to Defendants' Motion to Exclude Linda Bosserman (Rec. Doc. 6608).
 Sanofi filed Oppositions to the following Motions on March 29, 2019:
 - Opposition to Plaintiffs' Motion to Exclude David Spiegel (Rec. Doc. 6594); and

Opposition to Plaintiffs' Motion to Exclude Vivian Fonseca (Rec. Doc. 6593).

The remaining Motions, which are potentially affected by the untimely production of certain additional histological slides, are still being discussed, and the deadlines for filing Oppositions to such Motions will be determined by the Court at a later date.

On March 11, 2019, Trial Pool Plaintiff Kathleen Gabriel, who was selected for the Third Round of Plaintiffs, filed a Motion to Dismiss with a submission date of March 27, 2019. (Rec. Doc. 6496). Defendants' Opposition to this Motion was filed March 19, 2019. (Rec. Doc. 6534).

On March 18, 2019, Trial Pool Plaintiff Diana Warren, who was also selected for the Third Round of Plaintiffs, filed a Motion to Dismiss with a submission date of March 27, 2019. (Rec. Doc. 6530). The Opposition was filed on April 2, 2019. (Rec. Doc. 6669)

On March 22, 2019, Plaintiff filed a Motion to Remove Sheila Crayton from the Second Bellwether Trial Pool and to remove her as the alternate Plaintiff for the second bellwether trial. (Rec. Doc. 6559). The Opposition was filed on April 2, 2019. (Rec. Doc. 6670).

On March 25, 2019, the Court held a conference of liaison counsel in anticipation of which the parties submitted certain letter briefing for a proposed CMO (Amendment to Trial Pool Selection), along with the PSC's proposed redlines, to account for voluntary dismissal by Plaintiffs of Trial Pool cases, and to account for Trial Pool cases determined to be ineligible. The proposed CMO remains pending with the Court.

15. SPECIAL MASTER FOR PLAINTIFFS' TIME AND EXPENSES

In PTO 20 (Rec. Doc. 265), the Court appointed Kenneth W. DeJean as Special Master for the Plaintiffs to review the time and expenses submitted as common benefit during the course of the MDL. The Court has met with and communicated with the Special Master to discuss the time and expenses submitted on several occasions.

16. NEXT STATUS CONFERENCE

The next General Status Conference and meeting of Lead and Liaison Counsel will be scheduled by agreement of the Court and counsel. The Court will set up a telephone conference line for the status conference that will begin at 10:00 a.m. To join the status conference by telephone at 10:00 a.m., please use the call-in information on the Court's website under the tab "Upcoming Events."

Respectfully submitted:

/s/Dawn M. Barrios

Dawn M. Barrios (#2821)

Barrios, Kingsdorf & Casteix, LLP

701 Poydras Street, Suite 3650

New Orleans, LA 70139

Telephone: 504-524-3300 Facsimile: 504-524-3313

E-Mail: barrios@bkc-law.com

Plaintiffs' Co-Liaison Counsel

/s/M. Palmer Lambert

M. Palmer Lambert (#33228)

Gainsburgh Benjamin David Meunier

& Warshauer, LLC

2800 Energy Centre, 1100 Poydras Street

New Orleans, LA 70163-2800 Telephone: 504-522-2304

Facsimile: 504-528-9973

E-Mail: plambert@gainsben.com

Plaintiffs' Co-Liaison Counsel

/s/ Douglas J. Moore

Douglas J. Moore (Bar No. 27706)

IRWIN FRITCHIE URQUHART

& MOORE LLC

400 Poydras Street, Suite 2700

New Orleans, LA 70130

Telephone: 504-310-2100

Facsimile: 504-310-2120

E-Mail: dmoore@irwinllc.com

/s/ John F. Olinde

John F. Olinde (Bar No. 1515)

CHAFFE MCCALL, L.L.P.

1100 Poydras Street

New Orleans, LA 70163

Telephone: 504-585-7000

Facsimile: 504-585-7075

E-Mail: olinde@chaffe.com

Sanofi Defendants' Liaison Counsel

505(b)(2) Defendants' Liaison Counsel

CERTIFICATE OF SERVICE

I hereby certify that on, April 3, 2019, I electronically filed the foregoing with the Clerk of Court by using the CM/ECF system which will send a notice of electronic filing to all counsel of record who are CM/ECF participants.

/s/ Douglas J. Moore
Douglas J. Moore

APPENDIX A.16

Pretrial Orders

Pretrial Order No. 1 (Rec. Doc. 4) entered October 13, 2016 – Setting initial conference.

Pretrial Order No. 2 (Rec. Doc. 104) entered November 17, 2016 – Appointing Plaintiffs' Liaison Counsel, Plaintiffs' Steering Committee, and Defendants' Liaison Counsel.

Pretrial Order No. 3 (Rec. Doc. 115) entered November 30, 2016 – Filing Requests for Summons and Summons Returns.

Pretrial Order No. 4 (Rec. Doc. 122) entered December 9, 2016 – Procedures for Direct Filing into the MDL [superseded by PTO 5].

Pretrial Order No. 5 (Rec. Doc. 131) entered December 13, 2016 – Amended Procedures for Direct Filing into the MDL.

Pretrial Order No. 6 (Rec. Doc. 133) entered December 13, 2016 – Appointing Settlement Committees.

Pretrial Order No. 7 (Rec. Doc. 155) entered December 28, 2016 – Approving and attaching Counsel Contact Information Form.

Pretrial Order No. 8 (Rec. Doc. 156) entered December 30, 2016 – Federal-State Coordination and Cooperation.

Pretrial Order No. 9 (Rec. Doc. 160) entered January 3, 2017 – Streamlined Service on sanofi-Aventis U.S. LLC.

Pretrial Order No. 10 (Rec. Doc. 169) entered January 11, 2017 – JPML Clarification on Scope of MDL.

Pretrial Order No. 11 (Rec. Doc. 170) entered January 11, 2017 – Extending Deadline to Submit Proposed PFS and DFS.

Pretrial Order No. 12 (Rec. Doc. 191) entered January 20, 2017 – Directing that Service of Process shall be made on all known, non-sanofi Defendants by February 15, 2017; Directing Liaison Counsel to Provide Proposed Deadlines for Close of Pleadings.

Pretrial Order No. 13 (Rec. Doc. 209) entered January 31, 2017 – Appointing Brian S. Rudick to the Settlement Committee.

Pretrial Order No. 14 (Rec. Doc. 216) entered February 3, 2017 – Order from January 27, 2017 Status Conference.

Pretrial Order No. 15 (Rec. Doc. 230) entered February 10, 2017 – Order setting deadlines for Master and Short Form Complaint, Motions to Dismiss and Master Answer.

Pretrial Order No. 16 (Rec. Doc. 234) entered February 13, 2017 – Intention to Enter Common Benefit, Time and Expense Rules, Appointment of CPA, Holdback, Assessments, and Related Issues.

Pretrial Order No. 17 (Rec. Doc. 235) entered February 13, 2017 – Intention to Appoint Kenneth W. DeJean as Special Master.

Pretrial Order No. 18 (Rec. Doc. 236) entered February 14, 2017 – Ordering the use of the attached Plaintiff Fact Sheets and Defense Fact Sheets. See also R.Doc. 236-1.

Pretrial Order No. 19 (Rec. Doc. 262) entered February 23, 2017 – Adopting the proposed Common Benefit Order submitted by Liaison Counsel and the Plaintiffs' Steering Committee.

Pretrial Order No. 20 (Rec. Doc. 265) entered February 24, 2017 – Appointing Kenneth W. DeJean as Special Master.

Pretrial Order No. 21 (Rec. Doc. 276) entered March 7, 2017 – Setting Deadlines following March 6, 2017 meeting with liaison counsel.

Pretrial Order No. 22 (Rec. Doc. 279) entered March 10, 2017 – Implementation of Deadlines for Service of Fact Sheets and Deficiencies.

Pretrial Order No. 23 (Rec. Doc. 280) entered March 10, 2017 – Amending Exhibit A to Pretrial Order No. 18 (R. Doc. 236-1) to include the authorizations approved by the Court.

Pretrial Order No. 24 (R. Doc. 286) entered March 16, 2017 – Guidelines for service of Fact Sheets through MDL Centrality and Plaintiff Liaison Counsel Distribution of Orders and Notices per Pretrial Order No. 1.

Pretrial Order No. 25 (R. Doc. 287) entered March 16, 2017 – Appointing John F. Olinde to serve as Liaison Counsel for the non-Sanofi defendants.

Pretrial Order No. 26 (Rec. Doc. 289) entered March 17, 2017 – Designating Defense Counsel to Attend Plaintiffs' Steering Committee Meetings

Pretrial Order No. 26A (Rec. Doc. 598) entered June 28, 2017 – Modification to Designation of Defense Counsel to Attend Plaintiffs' Steering Committee Meetings

Pretrial Order No. 27 (Rec. Doc. 298) entered March 24, 2017 – Order from March 17, 2017 Status Conference

Pretrial Order No. 28 (Rec. Doc. 302) entered March 27, 2017 – Setting a Meeting with Liaison Counsel

Pretrial Order No. 29 (Rec. Doc. 303) entered March 27, 2017 – Streamlined Service on Accord Healthcare, Inc.

Pretrial Order No. 30 (Rec. Doc. 304) entered March 27, 2017 – Streamlined Service on Sandoz, Inc.

Pretrial Order No. 31 (Rec. Doc. 305) entered March 27, 2017 – Amended Task Codes for Common Benefit Order

Pretrial Order No. 32 (Rec. Doc. 307) entered March 31, 2017 – Streamlined Service on Actavis Pharma, Inc.

Pretrial Order No. 33 (Rec. Doc. 308) entered March 31, 2017 – Streamlined Service on McKesson Corporation

Pretrial Order No. 34 (Rec. Doc. 309) entered March 31, 2017 – Extending the Deadline to Submit Proposed Orders for Streamlined Service as to Eagle Pharmaceuticals, Inc. and NorthStar Rx LLC

Pretrial Order No. 35 (Rec. Doc. 310) entered March 31, 2017 – Scheduling Meetings between the Court and the Settlement Committees

Pretrial Order No. 36 (Rec. Doc. 317) entered April 6, 2017 – Withdrawal of Deadline to Submit Proposed Orders Regarding Streamlined Service as to Eagle Pharmaceuticals, Inc. and NorthStar Rx LLC

Pretrial Orders No. 37 and 41 (Rec. Docs. 318 and 331) entered April 6, 2017 and April 17, 2017 – Exemplar Short Form Complaint and superseding and amending Exemplar Short Form Complaint.

Pretrial Order No. 38 (Rec. Doc. 326) entered on April 12, 2017- Amending PFS and DFS

Pretrial Order No. 39 (Rec. Doc. 327) entered on April 11, 2017- Streamlined Service on Sun Pharma Global, Inc.

Pretrial Order No. 40 (Rec. Doc. 328) entered on April 12, 2017- Streamlined Service on Hospira Worldwide, LLC and Pfizer Inc.

Pretrial Order No. 40A (Rec. Doc. 509) entered June 1, 2017 – Amending Pretrial Order No. 40 regarding Streamlined Service on Hospira Worldwide, LLC and Pfizer, Inc.

Pretrial Order No. 42 (Rec. Doc. 348) entered on April 26, 2017- Responsive Pleadings to Short Form Complaints Reserved

Pretrial Order No. 43 (Rec. Doc. 349) entered April 27, 2017- Regarding July 7, 2017 Status Conference, 505(b)(2) Defendant Settlement Committee, "Science Day," Remand Motions and Discovery Schedule

Pretrial Order No. 44 (Rec. Doc. 371) entered May 11, 2017 – Order Appointing 505(b)(2) Defendants' Settlement Committee

Pretrial Order No. 45 (Rec. Doc. 458) entered May 12, 2017 – Setting the Briefing Schedule for the Omnibus Motions to Remand

Pretrial Order No. 46 (Rec. Doc. 462) entered May 16, 2017 – Order from May 12, 2017 Status Conference

Pretrial Order No. 47 (Rec. Doc. 534) entered June 13, 2017 – Granting Requests for Oral Argument on Omnibus Motions to Remand

Pretrial Order No. 48 (Rec. Doc. 566) entered June 28, 2017 – Resetting Oral Argument on Omnibus Motions to Remand

Pretrial Order No. 49 (Rec. Docs. 611, 613) entered July 5, 2017 – Electronically Stored Information Protocol

Pretrial Order No. 50 (Rec. Docs. 612, 613) entered July 5, 2017 – Protective Order

Pretrial Order No. 51 (Rec. Doc. 660) entered July 18, 2017- Order from July 7, 2017 Status Conference

Pretrial Order No. 52 (Rec. Doc. 661) entered July 18, 2017- Amended Deadlines Regarding Personal Jurisdiction and Potential Discovery Protocols

Pretrial Order No. 53 (Rec. Doc. 664) entered July 20, 2017- Amendments to Plaintiffs' Master Long Form Complaint, Exemplar Short Form Complaint and Plaintiffs' Fact Sheet

Pretrial Order No. 54 (Rec. Doc. 671) entered July 21, 2017- Docket Control Order- Voluntary Dismissals

Pretrial Order No. 55 (Rec. Doc. 688) entered July 25, 2017- Order Regarding the Filing of the Amended Master Long Form Complaint and Substitution of the Amended Exemplar Short Form Complaint and Amended Plaintiff Fact Sheet

Pretrial Order No. 56 (Rec. Doc. 712) entered August 2, 2017- Issuance of Summons with Corrected Defendants' Names

Pretrial Order No. 57 (Rec. Doc. 718) entered August 3, 2017- Setting a Meeting with Liaison Counsel

Pretrial Order No. 58 (Rec. Doc. 744) entered August 18, 2017- Granting Request for Oral Argument on Defendants' Motion to Dismiss Plaintiffs' Master Long Form Complaint (Rec. Doc. 489)

Pretrial Order No. 59 (Rec. Doc. 816) entered September 7, 2017- Resetting the Submission Date on Defendants' Motion to Dismiss Claims Barred by the Applicable Statutes of Limitations (Rec. Doc. No. 494)

Pretrial Order No. 60 (Rec. Doc. 819) entered September 7, 2017- Ordering Collection of Data of Potential Claimants by the Plaintiffs' Settlement Committee.

Pretrial Order No. 60A (Rec. Doc. 870) entered September 15, 2017- Amending and Superseding Order Regarding Collection of Data of Potential Claimants by the Plaintiffs' Settlement Committee.

Pretrial Order No. 61 (Rec. Doc. 877) entered September 27, 2017- Ordering the Dismissal of Count Two and Count Eight of the Master Long Form Complaint (Rec. Doc. 489).

Pretrial Order No. 62 (Rec. Doc. 878) entered September 27, 2017- Ordering that the deadline for each Defendant to file their Master Answer be set for Monday, October 16, 2017.

Pretrial Order No. 63 (Rec. Doc. 879) entered September 27, 2017- Ordering that the meeting of liaison counsel with the Court take place on Friday, October 6, 2017, at 9:30 a.m.

Pretrial Order No. 64 (Rec. Doc. 941) entered October 13, 2017- Ordering Clarifying the Court's Ruling (Rec. Doc. 784) on California Plaintiffs' Motion to Remand.

Pretrial Order No. 65 (Rec. Doc. 959) entered October 16, 2017- Ordering Severance of Multi-Plaintiff Cases.

Pretrial Order No. 66 (Rec. Doc. 1018) entered October 25, 2017- Order Clarifying this Court's Ruling on Delaware Motion to Remand (Rec. Doc. 784).

Pretrial Order No. 67 (Rec. Doc. 1032) entered October 27, 2017 – Order setting the next liaison counsel meeting for November 17, 2017, at 9:30 AM, and setting the next General Status Conference for December 15, 2017, at 10:00 AM.

Pretrial Order No. 68 (Rec. Doc. 1085) entered November 9, 2017- Setting Deadlines following October 27, 2017 meeting with Steering Committees.

Pretrial Order No. 69 (Rec. Doc. 1095) entered November 14, 2017- Setting Deadline for submission of applications for Court appointed positions with MDL 2740.

Pretrial Order No. 70 (Rec. Doc. 1137) entered November 21, 2017- Order regarding contact with physicians.

Pretrial Order No. 71 (Rec. Doc. 1306) entered December 15, 2017- Order governing Plaintiffs' responsibilities relevant to ESI.

Pretrial Order No. 72 (Rec. Doc. 1462) entered January 4, 2018 regarding dismissal of the French Sanofi Defendants per Stipulation.

Pretrial Order No. 73 (Rec. Doc. 1463) entered January 4, 2018 regarding Revised Exemplar Short Form Complaint.

Pretrial Order No. 74 (Rec. Doc. 1470) entered January 4, 2018 regarding Procedures for Withdrawal of Counsel.

Pretrial Order No. 75 (Rec. Doc. 1507) entered January 12, 2018 regarding Reappointment of Counsel in MDL 2740.

Pretrial Order No. 70A (Rec. Doc. 1528) replacing Pretrial Order No. 70 entered January 26, 2018 regarding Contact with Physicians.

Pretrial Order No. 71A (Rec. Doc. 1531) replacing Pretrial Order No. 71 entered January 26, 2018 regarding Plaintiffs' Responsibilities Relevant to ESI.

Pretrial Order No. 77 (Rec. Doc. 1633) entered February 7, 2018 regarding Additional California Plaintiffs' Motions to Remand.

Pretrial Order No. 37A (Rec. Doc. 1682) entered February 14, 2018 regarding Procedures for Short Form Complaints and Motions for Leave to Amend Short Form Complaints (supersedes Pretrial Order No. 37 (Rec. Doc. 318)).

Pretrial Order No. 77A (Rec. Doc. 2202) entered April 11, 2018 – Replacing Pretrial Order No. 77 Regarding California Plaintiffs' Motion to Remand

Pretrial Order No. 44A (Rec. Doc. 2355) entered April 25, 2018 – Replacing Pretrial Order No. 44 Replacing Settlement Counsel for Accord Healthcare, Inc. and Sandoz, Inc.

Pretrial Order No. 78 (Rec. Doc. 2147) entered April 6, 2018, setting the next general status conference for April 26, 2018 at 10:00 a.m.

Pretrial Order No. 79 (Rec. Doc. 3063) entered June 13, 2018, setting the next general status conference for July 18, 2018 at 10:30 a.m.

Pretrial Order No. 80 (Rec. Doc. 3472) entered July 19, 2018, setting the next general status conference for August 16, 2018 at 10:30 a.m.

Pretrial Order No. 22A (Rec. Doc. 3493) entered July 19, 2018, provides the show cause process for PFS deficiencies and for alleged failures to comply with CMO 12A and PTO 71A.

Pretrial Order No. 81 (Rec. Doc. 3906) entered August 21, 2018, setting the next general status conference for September 27, 2018 at 10:00 a.m.

Pretrial Order No. 82 (Rec. Doc. 4230) entered September 21, 2018, regarding the procedure for adding Sagent Pharmaceuticals, Inc.

Pretrial Order No. 83 (Rec. Doc. 4263) entered September 24, 2018, regarding streamlined service on Sagent Pharmaceuticals, Inc.

Pretrial Order No. 84 (Rec. Doc. 4525) entered October 4, 2018, setting the next general status conference for November 15, 2018 at 10:00 a.m.

Pretrial Order No. 70B (Rec. Doc. 5256) entered November 13, 2018 replacing Pretrial Order No. 71A regarding contact with physicians.

Pretrial Order No. 85 (Rec. Doc. 5257) entered November 13, 2018 establishing protocol for PTO 71A and privilege log deficiencies of non-bellwether plaintiffs before the Magistrate Judge.

Pretrial Order No. 86 (Rec. Doc. 5337) entered November 26, 2018, setting the next lead/liaison conference and show cause hearing for December 19, 2018.

Pretrial Order No. 87 (Rec. Doc. 5363) entered November 27, 2018, ordering procedures for dismissal with prejudice of any non-Trial Pool Plaintiff as to the entire action against all defendants in MDL No. 2740.

Pretrial Order No. 88 (Rec. Doc. 5376) entered November 28, 2018, ordering that John F. Olinde is reappointed as Defense Liaison Counsel for the 505(b)(2) Defendants and reappointing counsel to the 505(b)(2) Settlement Committee.

Pretrial Order No. 89 (Rec. Doc. 5377) entered November 28, 2018, ordering the reappointment of members to the Plaintiffs' Settlement Committee.

Pretrial Order No. 90 (Rec. Doc. 5379) entered November 28, 2018, ordering that Douglas J. Moore is reappointed as Defense Liaison Counsel for Defendants sanofi-aventis U.S. LLC and Sanofi U.S. Services Inc. and reappointing counsel to the Settlement Committee for sanofi-aventis U.S. LLC and Sanofi U.S. Services Inc.

Pretrial Order No. 91 (Rec. Doc. 5617) entered December 20, 2018, ordering that the next general status conference and show cause hearing will be held on January 18, 2019.

Pretrial Order No. 92 (Rec. Doc. 6016) entered January 29, 2019, setting a status conference for February 21, 2019.

Pretrial Order No. 93 (Rec. Doc. 6018) entered January 29, 2019, ordering that Plaintiffs' Liaison Counsel, Plaintiffs' Executive Committee, Plaintiffs' Steering Committee, and Plaintiffs' Federal-State Liaison Counsel are reappointed to their positions.

Pretrial Order No. 94 (Rec. Doc. 6516) entered March 12, 2019, setting a status conference for April 4, 2019 and providing the call-in number for counsel to listen, which is (800) 260-0712, and with access code 465448.

APPENDIX B.16

Case Management Orders

Case Management Order No. 1 (Rec. Doc. 465) entered May 18, 2017- Personal Jurisdiction Discovery

Case Management Order No. 2 (Rec. Doc. 474) entered May 23, 2017- Discovery on French Sanofi Entities

Case Management Order No. 3 (Rec. Doc. 669) entered July 21, 2017- Trial Scheduling Order

Case Management Order No. 4 (Rec. Doc. 670) entered July 21, 2017- Protocol for Initial Phase of Case-Specific Discovery for Cases Identified in Case Management Order No. 3

Case Management Order No. 5 (Rec. Doc. 762) entered August 23, 2017- General Discovery Protocol- Sanofi Defendants

Case Management Order No. 6 (Rec. Doc. 780) entered August 29, 2017- Setting Four Bellwether Trial Dates in 2019

Case Management Order No. 7 (Rec. Doc. 915) entered October 10, 2017- General Discovery Protocol – 505(b)(2) Defendants

Case Management Order No. 8 (Rec. Doc. 935) entered October 11, 2017- Trial Scheduling Order for MDL Trial No. 2

Case Management Order No. 8A (Rec. Doc. 1099) entered on November 14, 2017- That Amends and Supersedes CMO No. 8 (Trial Scheduling Order- MDL Trial No. 2)

Case Management Order No. 9 (Rec. Doc. 1110) entered on November 15, 2017- Deposition Protocol

Case Management Order No. 10 (Rec Doc 1168) entered on December 8, 2017 - Protocol for Initial Phase of Case-Specific Discovery re Cases in CMO 8A

Case Management Order No. 11 (Rec Doc 1430) entered on December 27, 2017 - Extension of Certain Deadlines in CMO 3

Case Management Order No. 12 (Rec. Doc. 1506) entered January 12, 2018 setting forth a Process for Obtaining Product Identification for Multi-Defendant Cases.

Case Management Order No. 13 (Rec. Doc. 1819) entered March 9, 2018 selecting First Bellwether Trial Plaintiffs Pursuant to Case Management Order No. 3.

Case Management Order No. 8B (Rec. Doc. 2444) entered May 3, 2018 amending Case Management Order No. 8A to Substitute Trial Plaintiff for MDL Trial No. 2.

Case Management Order No. 14 (Rec. Doc. 3064) entered June 13, 2018, entering the Trial Scheduling Order that replaced and superseded CMO Nos. 3, 4, 6, 8, 8A, 8B, 10, and 11.

Case Management Order No. 12A (Rec. Doc. 3492) entered July 24, 2018, providing the obligations and procedures governing discovery of Product ID Information and subsequent dismissal of defendants whose product was not used.

Case Management Order No. 14A (Rec. Doc. 5035) entered November 8, 2018, amending paragraphs 7.c. and 7.d. of CMO 14 (Rec. Doc. 3064).

Case Management Order No. 15 (Rec. Doc. 5008) entered November 8, 2018, establishing a pathology protocol for preservation and testing of tissue samples taken from Plaintiffs and handling of Plaintiffs' pathology slides. The CMO also provides forms for chain of custody and preservation letters to facilities.

Case Management Order No. 16 (Rec. Doc. 6017) entered January 29, 2019, naming Cynthia Thibodeaux as the primary Plaintiff in the second bellwether trial and Sheila Crayton as the alternate.

Case Management Order No. 17 (Rec. Doc. 6550) entered March 22, 2019, ordering that for any filing exceeding 50 pages in length, counsel is required to deliver a hard copy of the filing and all exhibits to the Court.

Case Management Order No. 18 (Rec. Doc. 6551) entered March 22, 2019, ordering that the first bellwether trial previously set for May 13-24, 2019, is continued to September 16-27, 2019.